Verrica Pharmaceuticals announced that a late‑breaking abstract reporting Phase 2 exploratory data for its oncolytic peptide VP‑315 has been accepted for presentation at the 2026 Society for Investigative Dermatology Annual Meeting in Chicago. The abstract, titled “VP‑315 Demonstrates Potential Abscopal Effect in Untreated Non‑Target Basal Cell Carcinoma (BCC) Tumors,” will be presented on May 15 2026, during the meeting’s May 13‑16 session at the Hilton Chicago.
VP‑315 is a first‑in‑class oncolytic peptide that is administered directly into a tumor to induce immunogenic cell death. The mechanism is designed to release tumor antigens and stimulate a systemic T‑cell response, potentially producing an abscopal effect where untreated tumors regress after local treatment. The abstract’s title highlights this systemic activity, a key feature that could broaden VP‑315’s therapeutic impact beyond the treated lesion.
In the Phase 2 exploratory study, 51 % of lesions achieved complete histological clearance and overall tumor size was reduced by 86 %. No dose‑limiting toxicities or treatment‑related serious adverse events were reported, underscoring the safety profile of VP‑315 in BCC patients. These data support the peptide’s potential as a non‑surgical option for the 3.6 million U.S. BCC cases diagnosed annually.
Verrica’s recent financial performance provides context for the significance of this development. In Q4 2025, the company generated $5.09 million in revenue, exceeding analyst expectations of $4.52 million, while GAAP net loss narrowed to $8.1 million from $16.2 million in Q4 2024. Revenue growth was driven by strong sales of its approved product YCANTH and collaboration revenue from Torii, and the company reduced selling, general, and administrative expenses by more than 40 %.
The acceptance of the VP‑315 abstract signals progress toward regulatory submission and may open partnership opportunities. By offering a non‑surgical therapeutic option, Verrica could capture a substantial share of the BCC market, addressing an unmet need for patients who cannot undergo surgery. The presentation at a major dermatology meeting will provide a platform for the scientific community to evaluate the data and could accelerate the company’s path to approval.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.